Novo Nordisk (NVO) has cemented itself as the leader in the booming weight-loss drug market with blockbuster treatments like ...

Morgan Stanley downgraded Novo Nordisk to underweight from equal-weight saying it sees slowing growth of its lucrative GLP-1 ...

Morgan Stanley analysts have downgraded Novo Nordisk’s stock, pointing in part to falling sales of weight-loss drugs Ozempic ...

Parker Waichman, a national law firm, has now filed multiple lawsuits where each Plaintiff alleged that he or she developed NAION after taking Novo ...

If you purchased or otherwise acquired Novo Nordisk securities between May 7, 2025 and July 28, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is ...

Novo Nordisk, the Danish maker of blockbuster drugs Ozempic and Wegovy, caught another downgrade Monday as analysts foresee ...

As India grapples with a surge in lifestyle-related illnesses, the approval of Ozempic marks more than just a new diabetes ...

Novo Nordisk was downgraded to underweight by Morgan Stanley. Morgan Stanley analysts say a trial to test whether Novo Nordisk's blockbuster weight-loss drug also will work against Alzheimer's is ...

Dutch start-up The Protein Brewery bets on mycoprotein Fermotein to thrive in a tough alt protein market, backed by €30m ...

Firm Novo Nordisk’s global patent is set to expire in parts of the world from early 2026, allowing cut-price ‘own-label’ ...

European companies, a major source of U.S. medicines, are hopeful that their investments and trade deals with the U.S. will ...